U.S. flag

An official website of the United States government

NM_005591.4(MRE11):c.1516G>T (p.Glu506Ter) AND Ataxia-telangiectasia-like disorder

Germline classification:
Pathogenic (2 submissions)
Last evaluated:
Feb 5, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000797374.8

Allele description [Variation Report for NM_005591.4(MRE11):c.1516G>T (p.Glu506Ter)]

NM_005591.4(MRE11):c.1516G>T (p.Glu506Ter)

Gene:
MRE11:MRE11 homolog, double strand break repair nuclease [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11q21
Genomic location:
Preferred name:
NM_005591.4(MRE11):c.1516G>T (p.Glu506Ter)
HGVS:
  • NC_000011.10:g.94456323C>A
  • NG_007261.1:g.42552G>T
  • NM_001330347.2:c.1516G>T
  • NM_005590.4:c.1516G>T
  • NM_005591.4:c.1516G>TMANE SELECT
  • NP_001317276.1:p.Glu506Ter
  • NP_005581.2:p.Glu506Ter
  • NP_005582.1:p.Glu506Ter
  • NP_005582.1:p.Glu506Ter
  • LRG_85t1:c.1516G>T
  • LRG_85:g.42552G>T
  • LRG_85p1:p.Glu506Ter
  • NC_000011.9:g.94189489C>A
  • NM_005590.3:c.1516G>T
  • NM_005591.3:c.1516G>T
  • p.E506*
Protein change:
E506*
Links:
dbSNP: rs587781384
NCBI 1000 Genomes Browser:
rs587781384
Molecular consequence:
  • NM_001330347.2:c.1516G>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_005590.4:c.1516G>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_005591.4:c.1516G>T - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
Ataxia-telangiectasia-like disorder (ATLD)
Identifiers:
MONDO: MONDO:0011457; MedGen: C1858391; OMIM: PS604391

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000936928Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Jan 16, 2024)
germlineclinical testing

PubMed (7)
[See all records that cite these PMIDs]

SCV004812942Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Feb 5, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Mre11 ATLD17/18 mutation retains Tel1/ATM activity but blocks DNA double-strand break repair.

Limbo O, Moiani D, Kertokalio A, Wyman C, Tainer JA, Russell P.

Nucleic Acids Res. 2012 Dec;40(22):11435-49. doi: 10.1093/nar/gks954. Epub 2012 Oct 17.

PubMed [citation]
PMID:
23080121
PMCID:
PMC3526295

Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms.

Regal JA, Festerling TA, Buis JM, Ferguson DO.

Hum Mol Genet. 2013 Dec 20;22(25):5146-59. doi: 10.1093/hmg/ddt368. Epub 2013 Aug 2.

PubMed [citation]
PMID:
23912341
PMCID:
PMC3842175
See all PubMed Citations (8)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000936928.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (7)

Description

This sequence change creates a premature translational stop signal (p.Glu506*) in the MRE11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MRE11 are known to be pathogenic (PMID: 23080121, 23912341). This variant is present in population databases (rs587781384, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with breast or ovarian cancer, fallopian tube cancer, and lung cancer (PMID: 24763289, 26786923, 26845104, 28125075). ClinVar contains an entry for this variant (Variation ID: 140941). For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV004812942.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

Variant summary: MRE11 c.1516G>T (p.Glu506X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 3.2e-05 in 250580 control chromosomes. c.1516G>T has been reported in the literature in individuals affected with Ataxia Telangiectasia-Like Disorder (Raslan_2021) . To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 33426167). ClinVar contains an entry for this variant (Variation ID: 140941). Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024